Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      GoHealth Reports Fourth Quarter and Fiscal 2020 Results

      Expects Continued Strong Growth in 2021

      GoHealth, Inc. (PRNewsfoto/GoHealth, Inc.)

      News provided by

      GoHealth, Inc.

      Mar 08, 2021, 16:42 ET

      Share this article

      Share this article


      CHICAGO, March 8, 2021 /PRNewswire/ -- GoHealth, Inc. (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced financial results for the three and twelve months ended December 31, 2020.

      • Fourth quarter 2020 net revenue of $445.9 million increased 55% compared to the prior year period, and fiscal year 2020 net revenue of $877.4 million increased 63% compared to the prior year period
      • Fourth quarter 2020 Medicare Advantage (MA) Submitted Policies of 330,604 increased 58% compared to the prior year period, and fiscal year 2020 MA Submitted Policies of 644,669 increased 81% compared to the prior year period
      • Fourth quarter 2020 LTV per carrier Approved MA Submission of $1,073 increased 5% compared to the prior year period, and fiscal year 2020 LTV per carrier Approved MA Submission of $995 increased 3% compared to the prior year period
      • Fourth quarter 2020 net income of $133.1 million and fiscal year 2020 net loss of $97.2 million (including $209.3 million of accelerated vesting of certain equity awards in connection with the IPO1)
      • Fourth quarter 2020 adjusted EBITDA2 of $169.9 million increased 31% compared to the prior year period, and fiscal year 2020 adjusted EBITDA of $271.0 million increased 59% compared to the prior year period
      • The Company provided its full year 2021 outlook, and expects total net revenue of $1,150 - $1,300 million (+31% to +48%) powered by commission revenue of $950 - $1,100 million (+42% to +64%).  The company also expects adjusted EBITDA of $345 - $385 million (+27% to +42%)


      Clint Jones, co-founder and CEO said, "GoHealth's fourth quarter revenue growth of 55% was driven by 75% revenue growth in our Internal Medicare segment, including LTV expansion of 5%.  These excellent top-line results reflect the great work of our agent force and a continuation of the strong full year trends where we grew revenue 63%, powered by a doubling of Internal Medicare revenue and leading to top-tier adjusted EBITDA margins of 31%.  We continue to see strong consumer demand for our services, particularly around education, transparency and choice when evaluating their Medicare options."
       

      Jones continued, "We are the largest and most profitable DTC Medicare enroller with 730,000 submissions in 2020, and with 75 million potential customers, we have a long runway for growth.  Our tech-enabled telesales agents are able to help consumers shop for the right plan to fit their unique needs, and do so from the safety and comfort of their homes.  Given the abundant opportunities in a fast-growing Medicare market, we are accelerating investments in our leadership position in 2021, including hiring more agents earlier in the year, and providing them with enhanced training and technology tools to deliver high-quality submissions with greater efficiency.  We believe that these investments in our platform will help drive over 50% commissionable revenue growth in 2021, and position us for sustained growth in 2022 and beyond."
       

      2020 Highlights

      (1)

      Total company revenue grew 63% to $877.4 million


      a.

      Total Medicare Submitted Policies3 grew 71% during 2020 to 729,912

      (2)

      Medicare—Internal revenue increased 110% to $667.3 million


      a.

      Medicare—Internal segment profit increased 79% to $296.9 million, with a 44% margin

      (3)

      Adjusted EBITDA grew 59% to $271.0 million, resulting in full-year adjusted EBITDA margins of 31%

      (4)

      LTV per carrier Approved MA Submission increased 3% to $995 during 2020

      (5)

      Grew commissions receivable balance by $427.5 million (+112%) in 2020 to $810.4 million

      Fourth Quarter AEP Highlights

      (1)

      Total company revenue grew 55% to $445.9 million


      a.

      Total Medicare Submitted Policies grew 48% during the fourth quarter to 374,359

      (2)

      Medicare—Internal revenue increased 75% to $351.1 million


      a.

      Medicare—Internal segment profit increased 40% to $172.9 million, with a 49% margin

      (3)

      Adjusted EBITDA grew 31% to $169.9 million, resulting in adjusted EBITDA margins of 38% as the company invested in internal lead generation and agent initiatives to drive persistency improvements


      a.

      LTV per carrier Approved MA Submission increased 5% to $1,073 during the fourth quarter

      2021 Financial Outlook

      The trajectory of the US economy remains challenging to predict, particularly given the continued uncertainty associated with the pace of recovery from the COVID-19 pandemic. During this time, demand for healthcare has demonstrated great resilience, and we believe that the COVID-19 pandemic has created favorable, long-term industry dynamics for technology-driven, direct-to-consumer models such as GoHealth's insurance marketplace.

      The Company has provided its financial outlook for the fiscal year ending December 31, 2021 based on current market conditions and expectations:

      (1)

      Full-year 2021 net revenue of $1,150 - $1,300 million, representing year-over-year growth of 31% - 48%


      a.

      Full-year 2021 commission revenue of $950 - $1,100 million, representing year-over-year growth of 42% - 64%, fueled by the Company's continued investment in its Medicare business

      (2)

      Full-year 2021 adjusted EBITDA of $345 - $385 million, representing year-over-year growth of 27% - 42%

      Conference Call Details

      The Company will host a conference call today, Monday, March 8, 2021 at 5:00 p.m. (ET) to discuss its financial results. A live audio webcast and a supplemental presentation will be available online at https://investors.gohealth.com. The conference call can also be accessed by dialing 1-833-519-1310 for U.S. participants, or 1-914-800-3876 for international participants, and referencing participant code 6590925. A replay of the call will be available for 30 days via webcast for on-demand listening shortly after the completion of the call, at the same web link.

      About GoHealth, Inc.:

      As a leading health insurance marketplace and Medicare-focused digital health company, GoHealth's mission is to improve access to healthcare in America. Enrolling in a health insurance plan can be confusing for customers, and the seemingly small differences between plans can lead to significant out-of-pocket costs or lack of access to critical medicines and even providers. GoHealth combines cutting-edge technology, data science and deep industry expertise to match customers with the healthcare policy and carrier that is right for them. Since its inception, GoHealth has enrolled millions of people in Medicare and individual and family plans. For more information, visit https://www.gohealth.com.

      Investor Relations:
      Jay Koval, VP of Investor Relations
      [email protected]

      Media Relations:
      [email protected]

      (1)

      Represents non-cash, share-based compensation expense relating to the accelerated vesting of performance-vesting units in connection with the IPO for the twelve months ended December 31, 2020.

      (2)

      Adjusted EBITDA is a non-GAAP measure. For a definition of Adjusted EBITDA and a reconciliation to the most comparable GAAP measure, please refer to the appendix.

      (3)

      Total Medicare Advantage Submitted Policies includes Commissionable and non-Commissionable Policies.

      Forward-Looking Statements

      This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding the Company's future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, statements regarding expected financial performance and operational performance for the fiscal year 2021 and first quarter of 2021, including with respect to revenue and Adjusted EBITDA are forward-looking statements. In some cases, you can identify forward-looking statements by terms, such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause the Company's actual results to differ materially from those indicated in these forward-looking statements, including, but are not limited to, the following: the Company's ability to comply with the numerous, complex and frequently changing laws regulating the marketing and sale of Medicare plans; the potential for an adverse change in the Company's relationships with carriers, including a loss of a carrier relationships; failure to grow the Company's customer base or retain its existing customers; carriers' ability to reduce commissions paid to the Company and adversely change their underwriting practices; significant consolidation in the healthcare industry which could adversely alter the Company's relationships with carriers; information technology systems failures or capacity constraints interrupting the Company's operations; factors that adversely impact the Company's estimate of LTV; the Company's dependence on agents to sell insurance plans; changes in the health insurance system and laws and regulation governing health insurance markets; the inability to effectively advertise the Company's products; and our ability to successfully implement our business plan during a global economic downturn caused by the COVID-19 pandemic.

      The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release, as well as the cautionary statements and other risk factors set forth in the Company's Quarterly Report on Form 10-Q for the third quarter ended September 30, 2020 and other SEC filings. If one or more events related to these or other risks or uncertainties materialize, or if the Company's underlying assumptions prove to be incorrect, actual results may differ materially from what the Company anticipates. Many of the important factors that will determine these results are beyond the Company's ability to control or predict. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, the Company does not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time-to-time, and it is not possible for us to predict which will arise. In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

      Use of Non-GAAP Financial Measures and Key Performance Indicators

      In this press release, we use supplemental measures of our performance that are derived from our consolidated financial information, but which are not presented in our Consolidated Financial Statements prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures include net income (loss) before interest expense, income tax expense (benefit) and depreciation and amortization expense, or EBITDA; Adjusted EBITDA and Adjusted EBITDA margin. Adjusted EBITDA is the primary financial performance measure used by management to evaluate its business and monitor its results of operations.

      Adjusted EBITDA represents EBITDA as further adjusted for share-based compensation, expense related to the accelerated vesting of certain equity awards, change in fair value of contingent consideration liability, Centerbridge Acquisition costs, severance costs and one time indirect costs in connection with our IPO. Adjusted EBITDA margin represents Adjusted EBITDA divided by net revenues.

      We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

      The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for net income (loss) prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA and Adjusted EBITDA to its most directly comparable GAAP financial measure, net income (loss), are presented in the tables below in this press release. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and include other expenses, costs and non-recurring items.

      Management has provided its outlook regarding adjusted EBITDA, which is a non-GAAP financial measure and excludes certain charges. Management has not reconciled these non-GAAP financial measures to the corresponding GAAP financial measures because guidance for the various reconciling items are not provided. Management is unable to provide guidance for these reconciling items because we cannot determine their probable significance, as certain items are outside of our control and cannot be reasonably predicted since these items could vary significantly from period to period. Accordingly, reconciliations to the corresponding GAAP financial measures are not available without unreasonable effort.

      "LTV/CAC" refers to the Lifetime Value of Commissions per Consumer Acquisition Cost, which we define as (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Approved Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints, or LTV, divided by (ii) the cost to convert a prospect into a customer less other non-commission carrier revenue for such period, or CAC. CAC is comprised of cost of revenue, marketing and advertising expenses and customer care and enrollment expenses less other revenue and is presented on a per commissionable Approved Submission basis. "Approved Submissions" refer to Submitted Policies approved by carriers for the identified product during the indicated period. "LTV Per Approved Submission" refers to the Lifetime Value of Commissions per Approved Submission, which we define as (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Approved Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints, divided by (ii) the number of commissionable Approved Submissions for such period.

      Combined Results

      On September 13, 2019, Centerbridge Capital Partners III, L.P., indirectly through a subsidiary of GoHealth Holdings, LLC, (formerly known as Blizzard Parent, LLC), an entity formed in contemplation of the acquisition, acquired a 100% interest in Norvax, LLC. We refer to this transaction as the "Centerbridge Acquisition." As a result of the Centerbridge Acquisition, the Company's financial results for the year ended December 31, 2019 are presented for two periods, the Predecessor 2019 Period and Successor 2019 Period, which relate to the period preceding the acquisition on September 13, 2019 and the period succeeding the acquisition, respectively. The Company's financial results for the period from January 1, 2019 through September 12, 2019 are referred to as those of the "Predecessor 2019 Period". The Company's financial results for the period from September 13, 2019 through December 31, 2019 are referred to as those of the "Successor 2019 Period". The Company's results of operations as reported in our Consolidated Financial Statements for these periods are prepared in accordance with GAAP. Although GAAP requires that we report on the Company's results for the period from January 1, 2019 through September 12, 2019 and the period from September 13, 2019 through December 31, 2019 separately, management views the Company's operating results for the year ended December 31, 2019 by combining the results of the applicable Predecessor 2019 Period and Successor 2019 Period because such presentation provides the most meaningful comparison to its results for the year ended December 31, 2020.

      The Company cannot adequately benchmark the operating results of the period from September 13, 2019 through December 31, 2019 against any of the current periods reported in its Consolidated Financial Statements without combining it with the period from January 1, 2019 through September 12, 2019 and does not believe that reviewing the results of this period in isolation would be useful in identifying trends in or reaching conclusions regarding the Company's overall operating performance. Management believes that the key performance metrics such as revenue, net (loss) income and Adjusted EBITDA for the Successor period when combined with the Predecessor period provides more meaningful comparisons to other periods and are useful in identifying current business trends. Accordingly, in addition to presenting the Company's results of operations as reported in our Consolidated Financial Statements in accordance with GAAP, the tables and discussion throughout this press release also present the combined results for the year ended December 31, 2019.

      The combined results for the year ended December 31, 2019, which we refer to herein as the results for the "year ended December 31, 2019" represent the sum of the reported amounts for the Predecessor 2019 Period from January 1, 2019 through September 12, 2019 and the Successor 2019 Period from September 13, 2019 through December 31, 2019. The combined results do not reflect the actual results the Company would have achieved had the Centerbridge Acquisition occurred on January 1, 2019 and may not be indicative of future results. These combined results are not considered to be prepared in accordance with GAAP and have not been prepared on a pro forma basis, which would reflect pro forma adjustments including, but not limited to: amortization expense for intangible assets, share-based compensation expense related to the Centerbridge Acquisition and the IPO, and transaction-related costs related to the Centerbridge Acquisition and the IPO.

      The following tables set forth the components of our results of operations for the periods indicated (unaudited):

      (in thousands, except percentages and per share amounts)

      Successor





      Three months ended Dec.

      31, 2020


      Three months ended Dec.

      31, 2019





      Dollars


      % of Net

      Revenues


      Dollars


      % of Net

      Revenues


      $ Change


      % Change

      Net revenues:












      Commission

      $

      360,634



      80.9

      %


      $

      229,624



      79.5

      %


      $

      131,010



      57.1

      %

      Enterprise

      85,289



      19.1

      %


      59,077



      20.5

      %


      26,212



      44.4

      %

      Net revenues

      445,923



      100.0

      %


      288,701



      100.0

      %


      157,222



      54.5

      %

      Operating expenses:












      Cost of revenue

      94,682



      21.2

      %


      85,648



      29.7

      %


      9,034



      10.5

      %

      Marketing and advertising

      96,309



      21.6

      %


      17,671



      6.1

      %


      78,638



      445.0

      %

      Customer care and enrollment

      60,229



      13.5

      %


      39,731



      13.8

      %


      20,498



      51.6

      %

      Technology

      9,530



      2.1

      %


      5,488



      1.9

      %


      4,042



      73.7

      %

      General and administrative

      19,828



      4.4

      %


      11,388



      3.9

      %


      8,440



      74.1

      %

      Change in fair value of contingent consideration liability

      —



      —

      %


      70,700



      24.5

      %


      (70,700)



      (100.0)

      %

      Amortization of intangible assets

      23,514



      5.3

      %


      23,514



      8.1

      %


      —



      —

      %

      Total operating expenses

      304,092



      68.2

      %


      254,140



      88.0

      %


      49,952



      19.7

      %

      Income from operations

      141,831



      31.8

      %


      34,561



      12.0

      %


      107,270



      310.4

      %

      Interest expense

      8,591



      1.9

      %


      6,787



      2.4

      %


      1,804



      26.6

      %

      Other (income) expense

      135



      —

      %


      (8)



      —

      %


      143



      N/M

      Income (loss) before income taxes

      133,105



      29.8

      %


      27,782



      9.6

      %


      105,323



      379.1

      %

      Income tax expense (benefit)

      5



      —

      %


      82



      —

      %


      (77)



      (93.9)

      %

      Net income (loss)

      $

      133,100



      29.8

      %


      $

      27,700



      9.6

      %


      $

      105,400



      380.5

      %

      Net income (loss) attributable to noncontrolling interests

      97,143



      21.8

      %









      Net income (loss) attributable to GoHealth, Inc.

      $

      35,957



      8.1

      %









      Net income (loss) per share:












      Net income (loss) per share of common stock — basic

      $

      0.43












      Net income (loss) per share of common stock — diluted (1)

      $

      0.41












      Weighted-average shares of common stock outstanding — basic

      84,194












      Weighted-average shares of common stock outstanding — diluted

      321,191












      Non-GAAP financial measures:












      EBITDA

      $

      166,806





      $

      58,512








      Adjusted EBITDA

      $

      169,889





      $

      129,782








      Adjusted EBITDA margin

      38.1

      %




      45.0

      %







      _________________________

      NM = Not meaningful

      (1)

      Net income per share of common stock - diluted of $0.41 is calculated by dividing net income of $133.1 million, which considers the reallocation of earnings after the assumed conversion of Class B Common Stock for Class A Common Stock, by the weighted-average shares of common stock outstanding - diluted of 321,191.

      (in thousands, except percentages
      and per share amounts)

      Successor


      Predecessor


      Non-GAAP Combined





      Twelve months ended Dec.

      31, 2020


      Period from

      Sep. 13, 2019

      through Dec.

      31, 2019


      Period from

      Jan. 1, 2019

      through Sep.

      12, 2019


      Twelve months ended Dec.

      31, 2019





      Dollars


      % of Net

      Revenues


      Dollars


      Dollars


      Dollars


      % of Net

      Revenues


      $ Change


      % Change

      Net revenues:
















      Commission

      $

      671,140



      76.5

      %


      $

      243,347



      $

      175,834



      $

      419,181



      77.7

      %


      $

      251,959



      60.1

      %

      Enterprise

      206,210



      23.5

      %


      65,144


      55,176



      120,320



      22.3

      %


      85,890



      71.4

      %

      Net revenues

      877,350



      100.0

      %


      308,491


      231,010



      539,501



      100.0

      %


      337,849



      62.6

      %

      Operating expenses:















      Cost of revenue

      199,202



      22.7

      %


      90,384


      79,169



      169,553



      31.4

      %


      29,649



      17.5

      %

      Marketing and advertising

      206,864



      23.6

      %


      24,811


      37,769



      62,580



      11.6

      %


      144,284



      230.6

      %

      Customer care and enrollment

      165,497



      18.9

      %


      44,356


      49,149



      93,505



      17.3

      %


      71,992



      77.0

      %

      Technology

      59,348



      6.8

      %


      6,006


      40,312



      46,318



      8.6

      %


      13,030



      28.1

      %

      General and administrative

      197,229



      22.5

      %


      13,674


      79,219



      92,893



      17.2

      %


      104,336



      112.3

      %

      Change in fair value of
      contingent consideration
      liability

      19,700



      2.2

      %


      70,700


      —



      70,700



      13.1

      %


      (51,000)



      (72.1)

      %

      Amortization of intangible
      assets

      94,056



      10.7

      %


      28,217


      —



      28,217



      5.2

      %


      65,839



      233.3

      %

      Acquisition related transaction
      costs

      —



      —

      %


      6,245


      2,267



      8,512



      1.6

      %


      (8,512)



      (100.0)

      %

      Total operating expenses

      941,896



      107.4

      %


      284,393


      287,885



      572,278



      106.1

      %


      369,618



      64.6

      %

      Income (loss) from operations

      (64,546)



      (7.4)

      %


      24,098


      (56,875)



      (32,777)



      (6.1)

      %


      (31,769)



      96.9

      %

      Interest expense

      32,969



      3.8

      %


      8,076


      140



      8,216



      1.5

      %


      24,753



      301.3

      %

      Other (income) expense

      (358)



      —

      %


      (17)


      114



      97



      —

      %


      (455)



      N/M

      Income (loss) before income taxes

      (97,157)



      (11.1)

      %


      16,039


      (57,129)



      (41,090)



      (7.6)

      %


      (56,067)



      136.4

      %

      Income tax expense (benefit)

      43



      —

      %


      44


      (66)



      (22)



      —

      %


      65



      (295.5)

      %

      Net income (loss)

      $

      (97,200)



      (11.1)

      %


      $

      15,995


      $

      (57,063)



      $

      (41,068)



      (7.6)

      %


      $

      (56,132)



      136.7

      %

      Net loss attributable to
      noncontrolling interests

      (52,933)



      (6.0)

      %












      Net loss attributable to
      GoHealth, Inc.

      $

      (44,267)



      (5.0)

      %












      Net income (loss) per share:
















      Net income (loss) per share of
      common stock — basic and diluted

      $

      (0.22)
















      Weighted-average shares of
      common stock outstanding —
      basic and diluted

      84,189
















      Non-GAAP financial measures:
















      EBITDA

      $

      34,364





      $

      52,853



      $

      (52,742)



      $

      111








      Adjusted EBITDA

      $

      271,029





      $

      130,465



      $

      39,973



      $

      170,438








      Adjusted EBITDA margin

      30.9

      %




      42.3

      %


      17.3

      %


      31.6

      %







      _________________________

      NM = Not meaningful

      The following tables set forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods indicated (unaudited):

      (in thousands)


      Successor


      Three months

      ended Dec.

      31, 2020


      Three months

      ended Dec.

      31, 2019

      Net revenues


      $

      445,923



      $

      288,701


      Net income


      133,100



      27,700


      Interest expense


      8,591



      6,787


      Income tax expense


      5



      82


      Depreciation and amortization expense


      25,110



      23,943


      EBITDA


      166,806



      58,512


      Share-based compensation expense (1)


      3,083



      448


      Change in fair value of contingent consideration liability (2)


      —



      70,700


      Severance costs (3)


      —



      122


      Adjusted EBITDA


      $

      169,889



      $

      129,782


      Adjusted EBITDA margin


      38.1

      %


      45.0

      %

      _________________________

      (1)

      Represents non-cash, share-based compensation expense relating to stock options, restricted stock units and time-vesting units.

      (2)

      Represents the change in fair value of the contingent consideration liability due to the predecessor owners of the Company arising from the Centerbridge Acquisition.

      (3)

      Represents costs associated with the termination of employment.

      (in thousands)

      Successor


      Predecessor


      Non-GAAP

      Combined

      Twelve

      months

      ended Dec.

      31, 2020


      Period from

      Sep. 13, 2019

      through Dec.

      31, 2019


      Period from

      Jan. 1, 2019

      through Sep.

      12, 2019


      Twelve

      months

      ended Dec.

      31, 2019

      Net revenues

      $

      877,350



      $

      308,491



      $

      231,010



      $

      539,501


      Net income (loss)

      (97,200)



      15,995



      (57,063)



      (41,068)


      Interest expense

      32,969



      8,076



      140



      8,216


      Income tax expense (benefit)

      43



      44



      (66)



      (22)


      Depreciation and amortization expense

      98,552



      28,738



      4,247



      32,985


      EBITDA

      34,364



      52,853



      (52,742)



      111


      Share-based compensation expense (1)

      6,929



      448



      —



      448


      Accelerated vesting of certain equity awards (2)

      209,300



      —



      87,060



      87,060


      Change in fair value of contingent consideration liability (3)

      19,700



      70,700



      —



      70,700


      Centerbridge Acquisition costs (4)

      —



      6,245



      4,908



      11,153


      IPO transactions costs (5)

      659



      —



      —



      —


      Severance costs (6)

      77



      219



      747



      966


      Adjusted EBITDA

      $

      271,029



      $

      130,465



      $

      39,973



      $

      170,438


      Adjusted EBITDA margin

      30.9

      %


      42.3

      %


      17.3

      %


      31.6

      %

      _________________________

      (1)

      Represents non-cash share-based compensation expense relating to stock options, restricted stock units and time-vesting units.

      (2)

      Represents non-cash share-based compensation expense relating to the accelerated vesting of performance-vesting units in connection with the IPO for the twelve months ended December 31, 2020 and the accelerated vesting of profit interests and incentive share units in connection with the Centerbridge Acquisition for the period from January 1, 2019 through September 12, 2019.

      (3)

      Represents the change in fair value of the contingent consideration liability due to the predecessor owners of the Company arising from the Centerbridge Acquisition.

      (4)

      Represents legal, accounting, consulting, and other costs related to the Centerbridge Acquisition.

      (5)

      Represents legal, accounting, consulting, and other indirect costs associated with the Company's IPO.

      (6)

      Represents costs associated with the termination of employment.

      The following table summarizes share-based compensation expense by operating function for the periods indicated (unaudited):

      (in thousands)


      Successor


      Predecessor


      Twelve

      months

      ended Dec.

      31, 2020


      Period from

      Sep. 13, 2019

      through Dec.

      31, 2019


      Period from

      Jan. 1, 2019

      through Sep.

      12, 2019

      Marketing and advertising


      $

      24,890



      $

      53



      $

      1,674


      Customer care and enrollment


      12,599



      20



      —


      Technology


      33,085



      66



      27,059


      General and administrative


      145,655



      309



      58,327


      Total share-based compensation expense


      $

      216,229



      $

      448



      $

      87,060


      The following table sets forth our balance sheets for the periods indicated (unaudited):

      (in thousands, except per share amounts)

      Successor

      Dec. 31, 2020


      Dec. 31, 2019

      Assets




      Current assets:




      Cash and cash equivalents

      $

      144,234



      $

      12,276


      Accounts receivable, net of allowance for doubtful accounts of $1,045 in 2020 and $904 in 2019

      26,871



      24,461


      Receivable from NVX Holdings, Inc.

      3,395



      —


      Commissions receivable - current

      188,128



      101,078


      Prepaid expense and other current assets

      29,194



      5,954


      Total current assets

      391,822



      143,769


      Commissions receivable - non-current

      622,270



      281,853


      Other long-term assets

      2,072



      998


      Property, equipment, and capitalized software, net

      17,353



      6,339


      Intangible assets, net

      688,726



      782,783


      Goodwill

      386,553



      386,553


      Total assets

      $

      2,108,796



      $

      1,602,295


      Liabilities and Stockholders' / Members' Equity




      Current liabilities:




      Accounts payable

      $

      8,733



      $

      13,582


      Accrued liabilities

      26,926



      22,568


      Commissions payable - current

      78,478



      56,003


      Deferred revenue

      736



      15,218


      Current portion of long-term debt

      4,170



      3,000


      Other current liabilities

      8,328



      2,694


      Total current liabilities

      127,371



      113,065


      Non-current liabilities:




      Commissions payable - non-current

      182,596



      97,489


      Capital lease obligations, less current portion

      396,400



      288,233


      Contingent consideration

      —



      242,700


      Other non-current liabilities

      3,274



      664


      Total non-current liabilities

      582,270



      629,086


      Stockholders' / members' equity:




      Members' interest

      —



      860,161


      Class A common stock – $0.0001 par value; 1,100,000 shares authorized; 84,196 shares issued and outstanding at
      December 31, 2020

      8



      —


      Class B common stock – $0.0001 par value; 619,004 shares authorized; 236,997 shares issued and outstanding at
      December 31, 2020

      24



      —


      Preferred stock – $0.0001 par value; 20,000 shares authorized; no shares issued and outstanding at December 31, 2020

      —



      —


      Additional paid-in capital

      397,504



      —


      Accumulated other comprehensive income (loss)

      17



      (17)


      Accumulated deficit

      (18,802)



      —


      Total stockholders' equity attributable to GoHealth, Inc. / members' equity

      378,751



      860,144


      Non-controlling interests

      1,020,404



      —


      Total stockholders' / members' equity

      1,399,155



      860,144


      Total liabilities and stockholders' / members' equity

      $

      2,108,796



      $

      1,602,295


      The following table sets forth our statements of cash flows for the periods indicated (unaudited):

      (in thousands)

      Successor


      Predecessor

      Twelve

      months

      ended Dec.

      31, 2020


      Period from

      Sep. 13, 2019

      through Dec.

      31, 2019


      Period from

      Jan. 1, 2019

      through Sep.

      12, 2019

      Operating Activities






      Net income (loss)

      $

      (97,200)



      $

      15,995



      $

      (57,063)


      Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:






      Share-based compensation

      216,229



      448



      87,060


      Depreciation and amortization

      4,496



      521



      4,247


      Amortization of intangible assets

      94,056



      28,217



      —


      Amortization of debt discount and issuance costs

      2,430



      472



      —


      Change in fair value of contingent consideration

      19,700



      70,700



      —


      Other non-cash items

      (1,691)



      417



      150


      Changes in assets and liabilities, net of acquisition:






      Accounts receivable

      (1,647)



      (15,113)



      (108)


      Commissions receivable

      (427,467)



      (203,956)



      (63,448)


      Prepaid expenses and other assets

      (24,021)



      (2,316)



      1,325


      Accounts payable

      (5,340)



      5,031



      (1,981)


      Accrued liabilities

      4,358



      31



      17,860


      Deferred revenue

      (14,482)



      11,935



      1,926


      Commissions payable

      107,583



      80,828



      19,228


      Other liabilities

      8,779



      (2,494)



      85


      Net cash provided by (used in) operating activities

      (114,217)



      (9,284)



      9,281


      Investing Activities






      Acquisition of business, net of cash

      —



      (807,591)



      —


      Purchases of property, equipment and software

      (14,523)



      (2,419)



      (5,597)


      Net cash used in investing activities

      (14,523)



      (810,010)



      (5,597)


      Financing Activities






      Proceeds from issuance of Class A common stock sold in initial public offering, net of offering costs

      852,407



      —



      —


      Payment of partial consideration of the Blocker Merger

      (96,165)



      —



      —


      Purchase of LLC Interests

      (508,320)



      —



      —


      Settlement of Senior Preferred Earnout Units

      (100,000)



      —



      —


      Issuance of preferred units

      —



      541,263



      —


      Proceeds received upon issuance of common units

      10,000



      —



      —


      Partner distributions

      (400)



      —



      —


      Borrowings under term loans

      117,000



      300,000



      —


      Principal payments under term loans

      (3,878)



      (750)



      —


      Borrowings under revolving credit facilities

      —



      —



      56,534


      Payments under revolving credit facilities

      —



      —



      (59,915)


      Debt issuance cost payments

      (6,293)



      (9,283)



      —


      Principal payments under capital lease obligations

      (293)



      (351)



      (68)


      Advancement to NVX Holdings, Inc.

      (3,395)



      —



      —


      Net cash provided by (used in) financing activities

      260,663



      830,879



      (3,449)


      Effect of exchange rate changes on cash

      35



      (17)



      (32)


      Increase in cash and cash equivalents

      131,958



      11,568



      203


      Cash and cash equivalents at beginning of period

      12,276



      708



      505


      Cash and cash equivalents at end of period

      $

      144,234



      $

      12,276



      $

      708


      The following tables set forth operating segment results for the periods indicated (unaudited):

      (in thousands, except percentages)

      Successor





      Three months ended Dec.

      31, 2020


      Three months ended Dec.

      31, 2019





      Dollars


      % of Net

      Revenues


      Dollars


      % of Net

      Revenues


      $ Change


      % Change

      Net revenues:












      Medicare - Internal

      $

      351,082



      78.7

      %


      $

      201,115



      69.7

      %


      $

      149,967



      74.6

      %

      Medicare - External

      78,355



      17.6

      %


      55,286



      19.1

      %


      23,069



      41.7

      %

      IFP and Other - Internal

      10,473



      2.3

      %


      20,086



      7.0

      %


      (9,613)



      (47.9)

      %

      IFP and Other - External

      6,013



      1.3

      %


      12,214



      4.2

      %


      (6,201)



      (50.8)

      %

      Net revenues

      445,923



      100.0

      %


      288,701



      100.0

      %


      157,222



      54.5

      %

      Segment profit:












      Medicare - Internal

      172,920



      38.8

      %


      123,711



      42.9

      %


      49,209



      39.8

      %

      Medicare - External

      5,051



      1.1

      %


      9,849



      3.4

      %


      (4,798)



      (48.7)

      %

      IFP and Other - Internal

      4,087



      0.9

      %


      4,095



      1.4

      %


      (8)



      (0.2)

      %

      IFP and Other - External

      1,121



      0.3

      %


      89



      —

      %


      1,032



      N/M

      Segment profit

      183,179



      41.1

      %


      137,744



      47.7

      %


      45,435



      33.0

      %

      Corporate expense

      17,834



      4.0

      %


      8,969



      3.1

      %


      8,865



      98.8

      %

      Change in fair value of contingent consideration liability

      —



      —

      %


      70,700



      24.5

      %


      (70,700)



      (100.0)

      %

      Amortization of intangible assets

      23,514



      5.3

      %


      23,514



      8.1

      %


      —



      —

      %

      Interest expense

      8,591



      1.9

      %


      6,787



      2.4

      %


      1,804



      26.6

      %

      Other (income) expense

      135



      —

      %


      (8)



      —

      %


      143



      N/M

      Income before income taxes

      $

      133,105



      29.8

      %


      $

      27,782



      9.6

      %


      $

      105,323



      379.1

      %

      _________________________

      NM = Not meaningful

      (in thousands, except percentages)

      Successor


      Predecessor


      Non-GAAP Combined





      Twelve months ended

      Dec. 31, 2020


      Period from

      Sep. 13, 2019

      through Dec.

      31, 2019


      Period from

      Jan. 1, 2019

      through Sep.

      12, 2019


      Twelve months ended Dec.

      31, 2019





      Dollars


      % of Net

      Revenues


      Dollars


      Dollars


      Dollars


      % of Net

      Revenues


      $ Change


      % Change

      Net revenues:
















      Medicare - Internal

      $

      667,293



      76.1

      %


      $

      215,322



      $

      102,196



      $

      317,518



      58.9

      %


      $

      349,775



      110.2

      %

      Medicare - External

      155,660



      17.7

      %


      59,152


      55,981



      115,133



      21.3

      %


      40,527



      35.2

      %

      IFP and Other - Internal

      32,271



      3.7

      %


      20,850


      37,909



      58,759



      10.9

      %


      (26,488)



      (45.1)

      %

      IFP and Other - External

      22,126



      2.5

      %


      13,167


      34,924



      48,091



      8.9

      %


      (25,965)



      (54.0)

      %

      Net revenues

      877,350



      100.0

      %


      308,491


      231,010



      539,501



      100.0

      %


      337,849



      62.6

      %

      Segment profit:















      Medicare - Internal

      296,865



      33.8

      %


      126,210


      40,024



      166,234



      30.8

      %


      130,631



      78.6

      %

      Medicare - External

      5,944



      0.7

      %


      10,584


      4,893



      15,477



      2.9

      %


      (9,533)



      (61.6)

      %

      IFP and Other - Internal

      4,269



      0.5

      %


      1,650


      2,195



      3,845



      0.7

      %


      424



      11.0

      %

      IFP and Other - External

      1,910



      0.2

      %


      584


      1,748



      2,332



      0.4

      %


      (422)



      (18.1)

      %

      Segment profit

      308,988



      35.2

      %


      139,027


      48,860



      187,887



      34.8

      %


      121,101



      64.5

      %

      Corporate expense

      259,778



      29.6

      %


      9,767


      103,469



      113,236



      21.0

      %


      146,542



      129.4

      %

      Change in fair value of
      contingent consideration
      liability

      19,700



      2.2

      %


      70,700


      —



      70,700



      13.1

      %


      (51,000)



      (72.1)

      %

      Amortization of intangible
      assets

      94,056



      10.7

      %


      28,217


      —



      28,217



      5.2

      %


      65,839



      233.3

      %

      Transaction costs

      —



      —

      %


      6,245


      2,267



      8,512



      1.6

      %


      (8,512)



      (100.0)

      %

      Interest expense

      32,969



      3.8

      %


      8,076


      140



      8,216



      1.5

      %


      24,753



      301.3

      %

      Other (income) expense

      (358)



      —

      %


      (17)


      114



      97



      —

      %


      (455)



      N/M

      Income (loss) before income
      taxes

      $

      (97,157)



      (11.1)

      %


      $

      16,039



      $

      (57,129)



      $

      (41,090)



      (7.6)

      %


      $

      (56,067)



      136.4

      %

      _________________________

      NM = Not meaningful

      The following table presents the number of Submitted Policies by product for the Medicare segments for the three and twelve months ended December 31, 2020 and 2019, for those submissions that are commissionable (compensated through commissions received from carriers):


      Successor


      Successor


      Predecessor


      Combined


      Three

      months

      ended Dec.

      31, 2020


      Three

      months

      ended Dec.

      31, 2019


      Twelve

      months

      ended Dec.

      31, 2020


      Period from

      Sep. 13, 2019

      through Dec.

      31, 2019


      Period from

      Jan. 1, 2019

      through Sep.

      12, 2019


      Twelve

      months

      ended Dec.

      31, 2019

      Medicare Advantage

      330,604


      208,991


      644,669


      222,599


      134,173


      356,772

      Medicare Supplement

      2,955


      6,681


      9,119


      7,444


      11,205


      18,649

      Prescription Drug Plans

      10,293


      13,386


      16,762


      13,838


      7,675


      21,513

      Total Medicare - Commissionable Submitted Policies

      343,852


      229,058


      670,550


      243,881


      153,053


      396,934

      The following tables present the number of Approved Submissions by product relating to commissionable policies for the Medicare segments for the three and twelve months ended December 31, 2020 and 2019. Only commissionable policies are used to calculate our LTV.

      Medicare - Internal


      Successor


      Successor


      Predecessor


      Combined


      Three

      months

      ended Dec.

      31, 2020


      Three

      months

      ended Dec.

      31, 2019


      Twelve

      months

      ended Dec.

      31, 2020


      Period from

      Sep. 13, 2019

      through Dec.

      31, 2019


      Period from

      Jan. 1, 2019

      through Sep.

      12, 2019


      Twelve

      months

      ended Dec.

      31, 2019

      Medicare Advantage

      250,251


      151,029


      478,863


      159,969


      86,544


      246,513

      Medicare Supplement

      1,514


      1,653


      3,116


      1,852


      3,198


      5,050

      Prescription Drug Plans

      8,263


      8,630


      13,582


      8,943


      5,078


      14,021

      Total Medicare - Internal Commissionable Approved
      Submissions

      260,028


      161,312


      495,561


      170,764


      94,820


      265,584

      Medicare - External


      Successor


      Successor


      Predecessor


      Combined


      Three

      months

      ended Dec.

      31, 2020


      Three

      months

      ended Dec.

      31, 2019


      Twelve

      months

      ended Dec.

      31, 2020


      Period from

      Sep. 13, 2019

      through Dec.

      31, 2019


      Period from

      Jan. 1, 2019

      through Sep.

      12, 2019


      Twelve

      months

      ended Dec.

      31, 2019

      Medicare Advantage

      77,669


      50,411


      158,325


      53,852


      48,341


      102,193

      Medicare Supplement

      1,219


      3,460


      5,254


      3,926


      7,065


      10,991

      Prescription Drug Plans

      1,798


      4,756


      3,036


      4,895


      2,597


      7,492

      Total Medicare - External Commissionable Approved
      Submissions

      80,686


      58,627


      166,615


      62,673


      58,003


      120,676

      The following table presents the LTV per Approved Submission by product for the Medicare segments for the three and twelve months ended December 31, 2020 and 2019:


      Successor


      Successor


      Predecessor


      Non-GAAP

      Combined


      Three

      months

      ended Dec.

      31, 2020


      Three

      months

      ended Dec.

      31, 2019


      Twelve

      months

      ended Dec.

      31, 2020


      Period from

      Sep. 13, 2019

      through Dec.

      31, 2019


      Period from

      Jan. 1, 2019

      through Sep.

      12, 2019


      Twelve

      months

      ended Dec.

      31, 2019

      Medicare Advantage

      $

      1,073


      $

      1,019


      $

      995


      $

      1,018


      $

      888


      $

      968

      Medicare Supplement

      $

      683


      $

      934


      $

      849


      $

      936


      $

      911


      $

      920

      Prescription Drug Plans

      $

      215


      $

      213


      $

      215


      $

      213


      $

      194


      $

      206

      The following table presents the number of Submitted Policies by product for the Medicare segments for the three and twelve months ended December 31, 2020 and 2019, for those submissions that are non-commissionable (compensated via hourly fees and enrollment fees) and do not result in commission revenue:


      Successor


      Successor


      Predecessor


      Combined


      Three

      months

      ended Dec.

      31, 2020


      Three

      months

      ended Dec.

      31, 2019


      Twelve

      months

      ended Dec.

      31, 2020


      Period from

      Sep. 13, 2019

      through Dec.

      31, 2019


      Period from

      Jan. 1, 2019

      through Sep.

      12, 2019


      Twelve

      months

      ended Dec.

      31, 2019

      Medicare Advantage

      23,993


      16,770


      44,799


      17,775


      4,240


      22,015

      Medicare Supplement

      3,520


      3,951


      8,782


      4,185


      1,051


      5,236

      Prescription Drug Plans

      2,994


      2,886


      5,781


      3,041


      471


      3,512

      Total Medicare - Non-commissionable Submitted
      Policies

      30,507


      23,607


      59,362


      25,001


      5,762


      30,763

      The following table sets forth the components of our results of operations for each quarter of 2020 (unaudited):

      (in thousands)

      Successor

      Three

      months

      ended Mar.

      31, 2020


      Three

      months

      ended Jun.

      30, 2020


      Three

      months

      ended Sep.

      30, 2020


      Three

      months

      ended Dec.

      31, 2020


      Twelve

      months

      ended Dec.

      31, 2020

      Net revenues:










      Commission

      $

      112,510



      $

      96,606



      $

      101,390



      $

      360,634



      $

      671,140


      Enterprise

      28,500



      30,451



      61,970



      85,289



      206,210


      Net revenues

      141,010



      127,057



      163,360



      445,923



      877,350


      Operating expenses:










      Cost of revenue

      42,134



      36,559



      25,827



      94,682



      199,202


      Marketing and advertising

      26,073



      21,634



      62,848



      96,309



      206,864


      Customer care and enrollment

      23,978



      28,394



      52,896



      60,229



      165,497


      Technology

      4,593



      5,705



      39,520



      9,530



      59,348


      General and administrative

      10,491



      10,359



      156,551



      19,828



      197,229


      Change in fair value of contingent consideration liability

      4,400



      15,300



      —



      —



      19,700


      Amortization of intangible assets

      23,514



      23,514



      23,514



      23,514



      94,056


      Total operating expenses

      135,183



      141,465



      361,156



      304,092



      941,896


      Income (loss) from operations

      5,827



      (14,408)



      (197,796)



      141,831



      (64,546)


      Interest expense

      6,756



      8,986



      8,636



      8,591



      32,969


      Other (income) expense

      10



      (505)



      2



      135



      (358)


      Income (loss) before income taxes

      (939)



      (22,889)



      (206,434)



      133,105



      (97,157)


      Income tax expense (benefit)

      (2)



      (22)



      62



      5



      43


      Net income (loss)

      $

      (937)



      $

      (22,867)



      $

      (206,496)



      $

      133,100



      $

      (97,200)


      Net income (loss) attributable to noncontrolling interests

      —



      —



      (150,076)



      97,143



      (52,933)


      Net income (loss) attributable to GoHealth, Inc.

      $

      (937)



      $

      (22,867)



      $

      (56,420)



      $

      35,957



      $

      (44,267)


      The following table sets forth the share-based compensation expense embedded in the operating expense line items for each quarter of 2020 (unaudited):

      (in thousands)

      Successor

      Three

      months

      ended Mar.

      31, 2020


      Three

      months

      ended Jun.

      30, 2020


      Three

      months

      ended Sep.

      30, 2020


      Three

      months

      ended Dec.

      31, 2020


      Twelve

      months

      ended Dec.

      31, 2020

      Marketing and advertising

      $

      57


      $

      61


      $

      24,709


      $

      63


      $

      24,890


      Customer care and enrollment

      24



      32



      11,993



      550



      12,599


      Technology

      73



      83



      32,748



      181



      33,085


      General and administrative

      325



      421



      142,620



      2,289



      145,655


      Total share-based compensation

      $

      479


      $

      597


      $

      212,070


      $

      3,083


      $

      216,229


      The following table sets forth operating segment results for each quarter of 2020 (unaudited):

      (in thousands)

      Successor

      Three

      months

      ended Mar.

      31, 2020


      Three

      months

      ended Jun.

      30, 2020


      Three

      months

      ended Sep.

      30, 2020


      Three

      months

      ended Dec.

      31, 2020


      Twelve

      months

      ended Dec.

      31, 2020

      Net revenues:










      Medicare - Internal

      $

      95,287



      $

      87,201



      $

      133,723



      $

      351,082



      $

      667,293


      Medicare - External

      28,945



      28,108



      20,252



      78,355



      155,660


      IFP and Other - Internal

      8,632



      7,019



      6,147



      10,473



      32,271


      IFP and Other - External

      8,146



      4,729



      3,238



      6,013



      22,126


      Net revenues

      $

      141,010



      $

      127,057



      $

      163,360



      $

      445,923



      $

      877,350


      Segment profit:










      Medicare - Internal

      $

      41,735



      32,746



      49,464



      172,920



      296,865


      Medicare - External

      (322)



      495



      720



      5,051



      5,944


      IFP and Other - Internal

      481



      (54)



      (245)



      4,087



      4,269


      IFP and Other - External

      512



      130



      147



      1,121



      1,910


      Segment profit

      $

      42,406



      $

      33,317



      $

      50,086



      $

      183,179



      $

      308,988


      The following tables set forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for each quarter of 2020 (unaudited):

      (in thousands)

      Successor

      Three months

      ended Mar.

      31, 2020


      Three months

      ended Jun.

      30, 2020


      Three months

      ended Sep.

      30, 2020


      Three months

      ended Dec.

      31, 2020


      Twelve

      months

      ended Dec.

      31, 2020

      Net revenues

      $

      141,010



      $

      127,057



      $

      163,360



      $

      445,923



      $

      877,350


      Net income (loss)

      (937)



      (22,867)



      (206,496)



      133,100



      (97,200)


      Interest expense

      6,756



      8,986



      8,636



      8,591



      32,969


      Income tax expense (benefit)

      (2)



      (22)



      62



      5



      43


      Depreciation and amortization expense

      24,147



      24,518



      24,777



      25,110



      98,552


      EBITDA

      29,964



      10,615



      (173,021)



      166,806



      34,364


      Share-based compensation expense (1)

      479



      597



      2,770



      3,083



      6,929


      Accelerated vesting of certain equity awards (2)

      —



      —



      209,300



      —



      209,300


      Change in fair value of contingent consideration liability (3)

      4,400



      15,300



      —



      —



      19,700


      Other adjustments (4)

      77



      424



      235



      —



      736


      Adjusted EBITDA

      $

      34,920



      $

      26,936



      $

      39,284



      $

      169,889



      $

      271,029


      Adjusted EBITDA margin

      24.8

      %


      21.2

      %


      24.0

      %


      38.1

      %


      30.9

      %

      _________________________

      (1)

      Represents non-cash share-based compensation expense relating to stock options, restricted stock units and time-vesting units.

      (2)

      Represents non-cash share-based compensation expense relating to the accelerated vesting of performance-vesting units in connection with the IPO.

      (3)

      Represents the change in fair value of the contingent consideration liability due to the predecessor owners of the Company arising from the Centerbridge Acquisition.

      (4)

      Represents legal, accounting, consulting, and other indirect costs associated with the Company's IPO and costs associated with the termination of employment.

      SOURCE GoHealth, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.